Information Provided By:
Fly News Breaks for June 22, 2018
HRTX
Jun 22, 2018 | 08:37 EDT
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $66 after the company reported phase 2B results in the total knee arthroplasty and breast augmentation, as its HTX-011 data met the endpoints in both trials with superior pain relief. The analyst adds that Heron has now reported positive results from seven phase 2 trials across 5 different surgical models, while estimating the HTX-011 program to address surgical procedures in a target market of about 15M cases. Belanger keeps his Buy rating on Heron Therapeutics.
News For HRTX From the Last 2 Days
There are no results for your query HRTX
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.